Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE We found that blast phase of PV was characterized by overt myelodysplasia (n = 51, 88%); moderate to severe myelofibrosis (33 of 45, 73%); an abnormal karyotype (n = 51, 88%) that was often complex karyotype (n = 42, 72%); and gene mutations involving TP53 (55%), TET2 (27%), and DNMT3A (25%). 29285580 2018
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE Contrarily, DNA methylation genes (DNMT3A, IDH1, IDH2 and TET2) were mutated most often in PV (0·5) and less frequently in ET (0·23) and PMF (0·20), but without reaching statistical significance. 27447873 2016
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as "TET2-first patients"), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ("JAK2-first patients") had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro. 25671252 2015
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE These results show epigenetic differences between PMF and polycythemia vera/essential thrombocytosis and reveal methylomic signatures of ASXL1 and TET2 mutations. 23066032 2013
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE We investigated a group of pediatric patients diagnosed either with essential thrombocythemia (ET; N = 9) or polycythemia vera (PV; N = 4) according to WHO criteria (median age = 10 years; range 1.5-15 years) in whom direct sequencing was performed for the existence of genetic alterations in JAK2, MPL, TET2, ASXL1, CBL, IDH1, and IDH2. 22106054 2012
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE We have studied the mutational status of TET2 (complete coding region), ASXL1 (exon12), IDH1 (R132), IDH2 (R140 and R172), and c-CBL (exons 8 and 9) in 62 MPN patients (52 essential thrombocythemia (ET), five polycythemia vera (PV), and five primary myelofibrosis (PMF)) negative for both JAK2 (V617F and exon 12) and MPL (exon 10) mutations. 21904853 2012
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE We conclude that loss-of-function TET2 mutations are not the polycythemia vera initiating events and that the acquisition of TET2 somatic mutations may increase the aggressivity of the polycythemia vera clone. 21273266 2011
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis. 20671051 2010
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 SomaticCausalMutation disease ORPHANET TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. 19262601 2009
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. 19262601 2009
Entrez Id: 54790
Gene Symbol: TET2
TET2
0.400 GeneticVariation disease BEFREE TET2 mutations were mainly observed (10 of 12) in patients with primary myelofibrosis or patients with polycythemia vera or essential thrombocythemia who secondarily evolved toward myelofibrosis or acute myeloid leukemia. 19564637 2009